Associate Professor of Medicine, University Tex Houston
Oncology
Dr. Nicholas E. Papadopoulos, MD
|
|
Give Review
Nicholas Papadopoulos works in the field of Oncology. He studied medicine at Baylor College of Medicine. Nicholas Papadopoulos is also published. He has 72 publications published. The lastest publication: "Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.' Nicholas E. Papadopoulos, MD is registered with Medicare.
Publications
- Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.
- Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced Melanoma.
- A phase I study of decitabine with pegylated interferon α-2b in advanced Melanoma: impact on DNA methylation and lymphocyte populations.
- Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with meta...
- Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination.
- Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic Melanoma.
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients.
- BRAF, NRAS and KIT sequencing Analysis of spindle cell melanoma.
- Delayed Systemic Recurrence of Uveal Melanoma.
- Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with Brain metastases.
- Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic Melanoma.
- Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in Cancer patients with impaired liver function.
- Predictive factors for the development of Brain metastasis in advanced unresectable metastatic melanoma.
- Does complete response to Systemic therapy in patients with stage IV melanoma translate into long-term survival?
- Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma.
- Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
- Biochemotherapy in patients with advanced head and neck mucosal Melanoma.
- Prognostic factors that determine the long-term survival of patients with unresectable metastatic Melanoma.
- A phase II trial of arsenic trioxide in patients with metastatic Melanoma.
- Pilot study of high-dose, concurrent biochemotherapy for advanced Melanoma.
- Biochemotherapy in patients with metastatic anoRectal mucosal melanoma.
- Sphincter-sparing local excision and adjuvant radiation for Anal-rectal melanoma.
- Tumor volume as a prognostic factor for sarcomatosis.
- Sequential biochemotherapy versus chemotherapy for metastatic Melanoma: results from a phase III randomized trial.
- Leiomyosarcoma of renal vein.
- Initial clinical studies with copovithane.
- Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-Cell therapy.
- Treatment of hepatic metastases in ocular Melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin.
- Phase II trial of imatinib mesylate in patients with metastatic Melanoma.
- Activity of dasatinib against L576P KIT mutant melanoma: molecular, Cellular, and clinical correlates.
- Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas.
- Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
- Osteosarcoma chemotherapy effect: a prognostic factor.
- Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor...
- In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in Cancer patie...
- Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic Melanoma using two different schedules .
- Prognostic factors for survival in melanoma patients with Brain metastases.
- Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma Cells plus DETOX in patients with metastatic melanoma.
- Prognostic factors for survival of patients treated Systemically for disseminated melanoma.
- Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients ...
- Pharmacokinetic/pharmacodynamic Analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.
- Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic Melanoma.
- Phase II evaluation of paclitaxel by short intravenous infusion in metastatic Melanoma.
- Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas.
- Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy.
- Mechanism of the anti-tumour effect of biochemotherapy in Melanoma: preliminary results.
- Myxoid liposarcoma. Experience with chemotherapy.
- Myxoid Malignant fibrous histiocytoma: experience with chemotherapy.
- Recovery of sperm production after chemotherapy for Osteosarcoma.
- Phase II study of paclitaxel in patients with previously treated Osteosarcoma and its variants.
- A phase I trial of weekly lomustine in patients with advanced Cancer.
- Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of Melanoma.
- Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic Melanoma.
- Phase II evaluation of temozolomide in metastatic choroidal Melanoma.
- Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
- Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed Osteosarcoma.
- A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic Melanoma after chemotherapy.
- A pilot study with vincristine sulfate liposome infusion in patients with metastatic Melanoma.
- Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic Melanoma.
- A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV Melanoma.
- A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for Melanoma recurrence.
- The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV Melanoma.
- Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic Melanoma patients.
- The left ventricle as the first site of uveal Melanoma metastasis 13 years after treatment of the primary tumor.
- Pelvic computed tomography scans for surveillance in patients with primary Melanoma in the head and neck.
- Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal Melanoma.
- Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with Systemic chemotherapy.
- A phase II study of gefitinib in patients with metastatic Melanoma.
- Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal Melanoma.
- Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.
- Preoperative chemotherapy for Osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum.
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
Baylor College of Medicine -
University of Athens
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1154403368 | |
| NPPES Provider LastName | PAPADOPOULOS | |
| NPPES Provider FirstName | NICHOLAS | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 325.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 37.0 | |
| Percent Opioid Claims | 11.38 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154403368 |
| Last Name Of The Provider | PAPADOPOULOS |
| First Name Of The Provider | NICHOLAS |
| View All |
Similar Doctors
|
Dr. Paul Zhang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn A. Gold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth W. Rogg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeri Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin Musher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon M. Giordano, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony P. Conley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna S. Zhukovsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giora M. Mavligit, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Aaron J. Schueneman, MD
This Doctor is OpenDoctor Recommended.
|